drugset / Trial / NCT01661634

Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure

NCT01661634

Phase 3 Completed 2157 enrolled Cardiorentis Quintiles, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of a continuous intravenous (IV) ularitide infusion on the clinical status and outcome of patients with acute decompensated heart failure (ADHF).

Timeline

Start
2012-07
Primary completion
2015-11
Completion
2016-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ularitide Protein / enzyme biologic 15 unknown Intravenous

Indications